Related Experiment Video

Updated: Jun 26, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.3K

Targeting Nrf2 signaling pathway: new therapeutic strategy for cardiovascular diseases

Qi Wu1, Jiangting Yao1, Mengyun Xiao1

  • 1School of Medical Imaging, Bengbu Medical University, Bengbu, China.

Journal of Drug Targeting
|May 16, 2024
PubMed

Insights

Oxidative stress drives cardiovascular diseases (CVDs). Targeting the Nrf2 pathway, which regulates oxidative stress and inflammation, offers a promising therapeutic strategy for CVDs.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Oxidative Stress Research

Background:

  • Cardiovascular diseases (CVDs) are the primary global cause of mortality.
  • Oxidative stress (OS) is a key factor in the development and progression of CVDs.
  • Novel therapeutic strategies are urgently needed to address the high incidence and mortality rates of CVDs.

Purpose of the Study:

  • To review the mechanisms and actions of the Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.
  • To highlight the potential of Nrf2 as a therapeutic target for cardiovascular diseases.
  • To explore Nrf2's role in mitigating CVD pathogenesis.

Main Methods:

  • Literature review of scientific articles on Nrf2 and cardiovascular diseases.
  • Analysis of the molecular mechanisms underlying Nrf2 regulation of oxidative stress and inflammation.
  • Synthesis of current research on Nrf2's therapeutic potential in CVD models.

Main Results:

  • Nrf2 is expressed throughout the cardiovascular system.
  • The Nrf2 pathway plays a crucial role in regulating cellular responses to oxidative stress and inflammation.
  • Modulation of Nrf2 activity shows promise in preclinical studies for various CVDs.

Conclusions:

  • The Nrf2 pathway represents a significant therapeutic target for cardiovascular diseases.
  • Further research into Nrf2 activators could lead to novel treatments for CVDs.
  • Targeting Nrf2 may offer a protective effect against the pathogenesis of cardiovascular diseases.
Keywords:
Nrf2 activatorsNuclear factor erythroid 2-related factor 2 (Nrf2)cardiovascular diseases (CVDs)oxidative stress (OS)therapeutic strategy

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.3K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

368

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
493